Hermans WR, Rensing BJ, Foley DP, Tijssen JG, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. J Cardiovasc Pharmacol. 1993, 22 Suppl 4, S45-57.

Hermans WR, Foley DP, Rensing BJ, Serruys PW. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). Am Heart J. 1994 Mar, 127(3), 483-494. [PMID]: 8122593.

[No authors listed] Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation. 1992 Jul, 86(1), 100-110. [PMID]: 1535568.